Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2019 17:15 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

Company Completes $6.28 Million Registered Direct OfferingFavorable Data Reported in Glioblastoma Multiforme Phase 3 Run-in StudyPhase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke...
July 23, 2019 08:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients

CHARLOTTESVILLE, Va., July 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
May 28, 2019 16:05 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. Announces Closing of $6.45 Million Offering Priced At-the-Market

CHARLOTTESVILLE, Va., May 28, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously...
May 24, 2019 09:00 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. Announces $6.45 Million Registered Direct Offering & Private Placement

CHARLOTTESVILLE, Va., May 24, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced that it has entered into a...
May 23, 2019 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Receives Notice of Intention to Grant a Patent Related to Use of TSC in Combination with tPA in Ischemic Stroke from European Patent Office

Two Additional European Patents Issued CHARLOTTESVILLE, Va., May 23, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge...
May 09, 2019 16:05 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., May 09, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
March 20, 2019 09:00 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports 2018 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., March 20, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
February 11, 2019 16:00 ET | Source: Diffusion Pharmaceuticals Inc.

Poster Presented at International Stroke Conference Describing Diffusion’s On-Ambulance Phase 2 Trial with TSC for Treating Acute Stroke

CHARLOTTESVILLE, Va., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
January 04, 2019 09:00 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference

CHARLOTTESVILLE, Va., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
January 03, 2019 09:00 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Executes Successful NASDAQ Compliance Plan: Company Will Remain Listed on NASDAQ Stock Market

CHARLOTTESVILLE, Va., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right